Fig. S6
Small molecule screen for compounds that suppress larval liver enlargement caused by activated β-catenin. Transgenic zebrafish expressing activated β-catenin (Tg(fabp10a:pt-β-cat, cryaa:Venus)) were crossed to zebrafish expressing liver-specific GFP (Tg(fabp10a:EGFP). At 3 days old, larvae with green livers (fabp10a:EGFP+) were selected for drug treatment. Zebrafish with activated β-catenin, identified by their fluorescent eyes, were treated in parallel to control zebrafish without activated β-catenin. Three zebrafish were placed in each well, and 4 wells were tested for each experimental compound and vehicle (DMSO) control. Liver size was scored qualitatively 3 days post treatment (dpt). Drugs that decreased average liver size of Tg(fabp10a:pt-β-cat); Tg(fabp10a:EGFP) zebrafish in both wells compared to DMSO controls without causing toxicity/death in any wells were considered potential hit compounds. |